These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27776289)

  • 1. Why do subjects on clinical trials discontinue therapy? Do we really know?
    Medeiros BC; Gale RP
    Leuk Res; 2016 Dec; 51():19-21. PubMed ID: 27776289
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.
    Sankoh AJ; D'Agostino RB; Huque MF
    Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin adverse effects: sorting out the evidence.
    Mlodinow SG; Onysko MK; Vandiver JW; Hunter ML; Mahvan TD
    J Fam Pract; 2014 Sep; 63(9):497-506. PubMed ID: 25353029
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical trials with drugs: the influence of the authorization process].
    Carcas AJ; Serrano MA; Avendaño C; Galende I; Tristán C; García-Alonso F
    Med Clin (Barc); 1995 May; 104(18):683-8. PubMed ID: 7769877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now.
    Fonarow GC; Ballantyne CM
    Circulation; 2001 Jun; 103(23):2768-70. PubMed ID: 11401927
    [No Abstract]   [Full Text] [Related]  

  • 6. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
    Naci H; Ioannidis JP
    Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can the frequency and risks of fatal adverse drug events be determined?
    Kelly WN
    Pharmacotherapy; 2001 May; 21(5):521-7. PubMed ID: 11349740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ISAT. Again..
    Figueiredo EG
    World Neurosurg; 2010 Jun; 73(6):601-3. PubMed ID: 20934133
    [No Abstract]   [Full Text] [Related]  

  • 9. A confidence interval for the ratio of treatment variances in a two-by-two crossover study.
    Bristol DR
    J Biopharm Stat; 1991; 1(2):237-45. PubMed ID: 1844699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare adverse events in clinical trials: understanding the rule of three.
    Onakpoya IJ
    BMJ Evid Based Med; 2018 Feb; 23(1):6. PubMed ID: 29367316
    [No Abstract]   [Full Text] [Related]  

  • 11. Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives.
    Jacobson NS; Roberts LJ; Berns SB; McGlinchey JB
    J Consult Clin Psychol; 1999 Jun; 67(3):300-7. PubMed ID: 10369050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems from the past and prevention for the future.
    Patten SB
    Can J Psychiatry; 2015 Jan; 60(1):4-5. PubMed ID: 25886542
    [No Abstract]   [Full Text] [Related]  

  • 13. [How to measure patient-important outcomes in clinical studies].
    Klaghofer R; Puhan MA
    Ther Umsch; 2007 Dec; 64(12):673-7. PubMed ID: 18581915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical trials. An overview].
    Wegscheider K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):515-23. PubMed ID: 15887060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstrating drug action.
    Tamminga CA
    Am J Psychiatry; 2004 Jun; 161(6):943-5. PubMed ID: 15169679
    [No Abstract]   [Full Text] [Related]  

  • 16. Expanding roles of hospital epidemiology: pharmacoepidemiology.
    Burke JP; Tilson HH; Platt R
    Infect Control Hosp Epidemiol; 1989 Jun; 10(6):253-4. PubMed ID: 2661681
    [No Abstract]   [Full Text] [Related]  

  • 17. Withdrawing from the treatment does not mean from the study.
    Cobo E; Stephen S; Elmore M
    Bull World Health Organ; 2008 Oct; 86(10):C. PubMed ID: 18949201
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating patient-based outcome measures for use in clinical trials.
    Fitzpatrick R; Davey C; Buxton MJ; Jones DR
    Health Technol Assess; 1998; 2(14):i-iv, 1-74. PubMed ID: 9812244
    [No Abstract]   [Full Text] [Related]  

  • 19. Using acquired knowledge and new technologies in alcoholism treatment trials.
    Flannery BA; Allen JP; Pettinati HM; Rohsenow DJ; Cisler RA; Litten RZ
    Alcohol Clin Exp Res; 2002 Mar; 26(3):423-9. PubMed ID: 11923598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation.
    Pocock SJ
    Control Clin Trials; 1997 Dec; 18(6):530-45; discussion 546-9. PubMed ID: 9408716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.